RU2004129324A - Применения бисфосфоновых кислот для лечения и профилактики остеопороза - Google Patents
Применения бисфосфоновых кислот для лечения и профилактики остеопороза Download PDFInfo
- Publication number
- RU2004129324A RU2004129324A RU2004129324/15A RU2004129324A RU2004129324A RU 2004129324 A RU2004129324 A RU 2004129324A RU 2004129324/15 A RU2004129324/15 A RU 2004129324/15A RU 2004129324 A RU2004129324 A RU 2004129324A RU 2004129324 A RU2004129324 A RU 2004129324A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- bisphosphonic acid
- use according
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (14)
1. Применение бисфосфоновой кислоты или ее фармацевтически приемлемой соли для приготовления лекарственного средства для профилактики или лечения заболеваний, характеризующихся паталогически повышенной костной резорбцией, которое
а) содержит по крайней мере 120% ожидаемой эффективной суточной дозы бисфосфоновой кислоты или ее фармацевтически приемлемой соли и один или несколько фармацевтически приемлемых эксципиентов и
б) лекарственное средство вводят орально в течение одних, двух или трех суток подряд в месяц.
2. Применение по п.1, где заболевание является остеопорозом.
3. Применение по п.1 или 2, где эффективная доза составляет примерно от 100 до 150 мг бисфосфоновой кислоты или ее фармацевтически приемлемой соли.
4. Применение по п.1, где бисфосфоновой кислотой является ибандроновая кислота или ее фармацевтически приемлемые соли.
5. Применение по п.1, где эффективная доза составляет примерно 100 мг бисфосфоновой кислоты или ее фармацевтически приемлемой соли.
6. Применение по п.1, где эффективная доза составляет примерно 150 мг бисфосфоновой кислоты или ее фармацевтически приемлемой соли.
7. Применение по п.1 или 5, где бисфосфоновая кислота или ее фармацевтически приемлемая соль представлена моногидратом мононатриевой соли ибандроновой кислоты.
8. Применение по п.1 или 6, где бисфосфоновая кислота или ее фармацевтически приемлемая соль представлена моногидратом мононатриевой соли ибандроновой кислоты.
9. Применение по п.1, где лекарственное средство является таблеткой с пленочным покрытием, в которой ядро таблетки содержит от 50 до 250 мг бисфосфоновой кислоты или ее фармацевтически приемлемой соли, как указано в пп.1-7, и один или более фармацевтически приемлемый эксципиент, выбранный из группы, включающей лактозу, поливинилпирролидон, микрокристаллическую целлюлозу, кросповидон, стеариновую кислоту, диоксид кремния, также ядро таблетки содержит один или более фармацевтически приемлемый эксципиент, выбранный из группы, включающей гидроксипропилметилцеллюлозу, диоксид титана, тальк и полиэтиленгликоль 6000.
10. Применение по п.1, где лекарственное средство вводится как разовая доза.
11. Применение по п.1, где лекарственное средство вводится в виде нескольких суб-доз.
12. Способ лечения или профилактики заболеваний, характеризующихся паталогически повышенной костной резорбцией, включающий оральное введение эффективного количества бисфосфоновой кислоты или ее фармацевтически приемлемой соли, по которому от 50 до 250 мг бисфосфоновой кислоты или ее фармацевтически приемлемой соли вводится в течение месяца за одни сутки или двое суток подряд.
13. Способ по п.12, в где бисфосфоновая кислота является ибандроновой кислотой или ее фармацевтически приемлемой солью.
14. Способ по п.12 или 13, где бисфосфоновая кислота или ее фармацевтически приемлемая соль вводится как указано в п.1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02010136.6 | 2002-05-10 | ||
EP02010136 | 2002-05-10 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008103617/14A Division RU2387451C2 (ru) | 2002-05-10 | 2003-05-02 | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2004129324A true RU2004129324A (ru) | 2006-01-27 |
RU2329809C2 RU2329809C2 (ru) | 2008-07-27 |
Family
ID=29414669
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2004129324/15A RU2329809C2 (ru) | 2002-05-10 | 2003-05-02 | Применения бисфосфоновых кислот для лечения и профилактики остеопороза |
RU2008103617/14A RU2387451C2 (ru) | 2002-05-10 | 2003-05-02 | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008103617/14A RU2387451C2 (ru) | 2002-05-10 | 2003-05-02 | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза |
Country Status (33)
Country | Link |
---|---|
US (5) | US7410957B2 (ru) |
EP (4) | EP1880744B1 (ru) |
JP (5) | JP2005522526A (ru) |
KR (7) | KR20120065435A (ru) |
CN (2) | CN1939314A (ru) |
AR (2) | AR039978A1 (ru) |
AT (1) | ATE376444T1 (ru) |
AU (2) | AU2003229770B2 (ru) |
BR (1) | BR0308901A (ru) |
CA (2) | CA2481142C (ru) |
CY (2) | CY1108105T1 (ru) |
DE (1) | DE60317061T2 (ru) |
DK (2) | DK1506041T3 (ru) |
EC (1) | ECSP045335A (ru) |
ES (2) | ES2532393T3 (ru) |
GT (1) | GT200300107A (ru) |
HK (1) | HK1080409A1 (ru) |
HR (1) | HRP20040906B1 (ru) |
IL (3) | IL164371A0 (ru) |
MX (1) | MXPA04009586A (ru) |
MY (2) | MY146809A (ru) |
NO (2) | NO328734B1 (ru) |
NZ (2) | NZ556278A (ru) |
PA (1) | PA8573101A1 (ru) |
PE (1) | PE20040440A1 (ru) |
PL (2) | PL371346A1 (ru) |
PT (2) | PT1880744E (ru) |
RU (2) | RU2329809C2 (ru) |
SI (2) | SI1506041T1 (ru) |
TW (1) | TWI347188B (ru) |
UY (1) | UY27802A1 (ru) |
WO (1) | WO2003095029A1 (ru) |
ZA (1) | ZA200407950B (ru) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US7658938B2 (en) * | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
TWI349553B (en) * | 2001-12-21 | 2011-10-01 | Procter & Gamble | Kit and use of bisphosphonate for treating high bone turnover |
US20050070504A1 (en) * | 2001-12-21 | 2005-03-31 | The Procter & Gamble Co. | Risedronate compositions and their methods of use |
US20050176685A1 (en) * | 2002-04-05 | 2005-08-11 | Daifotis Anastasia G. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
MXPA04009586A (es) * | 2002-05-10 | 2005-01-11 | Hoffmann La Roche | Acidos bisfosfonicos para el tratamiento y prevencion de la osteoporosis. |
SI1596870T2 (sl) † | 2002-12-20 | 2011-07-29 | Hoffmann La Roche | Formulacija z visokim odmerkom ibandronata |
US20050261250A1 (en) * | 2004-05-19 | 2005-11-24 | Merck & Co., Inc., | Compositions and methods for inhibiting bone resorption |
CA2576659A1 (en) * | 2004-08-23 | 2006-03-02 | Teva Pharmaceutical Industries Ltd. | Solid and crystalline ibandronate sodium and processes for preparation thereof |
CA2594717C (en) * | 2005-02-01 | 2015-01-20 | F. Hoffmann-La Roche Ag | Ibandronate polymorph b |
BRPI0607092A2 (pt) * | 2005-02-01 | 2009-08-04 | Hoffmann La Roche | polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil) amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende |
US20070049557A1 (en) * | 2005-08-24 | 2007-03-01 | Hashim Ahmed | Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers |
US7704977B2 (en) * | 2006-04-07 | 2010-04-27 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
DE602007008222D1 (de) | 2006-04-20 | 2010-09-16 | Hoffmann La Roche | Diazepanderivate als modulatoren von chemokinrezeptoren |
EP2114455A4 (en) * | 2006-12-20 | 2010-03-17 | Mylan Pharmaceuticals Ulc | PHARMACEUTICAL COMPOSITION USING A HOT-MELT GRANULATED AGENT |
WO2009137078A1 (en) * | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
EP2210596A1 (en) | 2009-01-22 | 2010-07-28 | Laboratorios Liconsa, S.A. | Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof |
US20100215743A1 (en) * | 2009-02-25 | 2010-08-26 | Leonard Thomas W | Composition and drug delivery of bisphosphonates |
US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
JP5852569B2 (ja) | 2009-07-31 | 2016-02-03 | タール ファーマシューティカルズ,インコーポレイテッド | 結晶化方法および生物学的利用能 |
US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
US9089484B2 (en) * | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
KR20140026354A (ko) | 2011-01-07 | 2014-03-05 | 메리온 리서치 Ⅲ 리미티드 | 경구 투여용 철의 제약 조성물 |
JP5874545B2 (ja) * | 2011-06-20 | 2016-03-02 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
JP7211704B2 (ja) | 2015-01-29 | 2023-01-24 | ノヴォ ノルディスク アー/エス | Glp-1アゴニスト及び腸溶コーティングを含む錠剤 |
CN107011380A (zh) * | 2016-01-28 | 2017-08-04 | 臧伟 | 一种二膦酸衍生物及含二膦酸衍生物的组合物治疗骨折的应用 |
WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
Family Cites Families (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US500937A (en) * | 1893-07-04 | Conduit railway insulator | ||
US124314A (en) * | 1872-03-05 | Improvement in preparing paper for buildings | ||
DE2405254C2 (de) | 1974-02-04 | 1982-05-27 | Henkel KGaA, 4000 Düsseldorf | Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper |
DE2534391C2 (de) | 1975-08-01 | 1983-01-13 | Henkel KGaA, 4000 Düsseldorf | 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren |
DE2745083C2 (de) | 1977-10-07 | 1985-05-02 | Henkel KGaA, 4000 Düsseldorf | Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung |
US4252742A (en) | 1979-07-13 | 1981-02-24 | Ciba-Geigy Corporation | Chemical process for the preparation of 2,6-dialkylcyclohexylamines from 2,6-dialkylphenols |
DE2943498C2 (de) | 1979-10-27 | 1983-01-27 | Henkel KGaA, 4000 Düsseldorf | Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure |
DE3016289A1 (de) | 1980-04-28 | 1981-10-29 | Henkel KGaA, 4000 Düsseldorf | Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren |
IT1201087B (it) | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche |
FR2531088B1 (fr) | 1982-07-29 | 1987-08-28 | Sanofi Sa | Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation |
US4509612A (en) | 1982-09-28 | 1985-04-09 | Applied Power Inc. | Latch mechanism for a tilt-cab truck |
JPS59145179A (ja) | 1983-01-11 | 1984-08-20 | Ricoh Co Ltd | 補充交換用部品を検知可能にした事務機器 |
IT1195993B (it) | 1984-01-12 | 1988-11-03 | Gentili Ist Spa | Forme farmaceutiche a base di difosfonati |
DE3428524A1 (de) | 1984-08-02 | 1986-02-13 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
DE3434667A1 (de) | 1984-09-21 | 1986-04-03 | Henkel KGaA, 4000 Düsseldorf | 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung |
IT1196315B (it) | 1984-10-29 | 1988-11-16 | Gentili Ist Spa | Procedimento per la preparazione di acidi difosfonici |
US4812311A (en) | 1984-12-21 | 1989-03-14 | The Procter & Gamble Company | Kit for use in the treatment of osteoporosis |
DE3512536A1 (de) | 1985-04-06 | 1986-10-16 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US4761406A (en) | 1985-06-06 | 1988-08-02 | The Procter & Gamble Company | Regimen for treating osteoporosis |
DE3540150A1 (de) | 1985-11-13 | 1987-05-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
DE3623397A1 (de) | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
DE3626058A1 (de) | 1986-08-01 | 1988-02-11 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
DE3640938A1 (de) | 1986-11-29 | 1988-06-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel |
HU199151B (en) | 1987-03-10 | 1990-01-29 | Yamanouchi Pharma Co Ltd | Process for producing bis-phosphonic acid derivatives |
CA1339805C (en) | 1988-01-20 | 1998-04-07 | Yasuo Isomura | (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active |
DE3822650A1 (de) | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US4958839A (en) | 1988-07-12 | 1990-09-25 | Guzik Technical Enterprises, Inc. | Disc clamp employing resilient cone for spreading balls |
DE3825654A1 (de) * | 1988-07-28 | 1990-02-01 | Bosch Gmbh Robert | Sicherheitseinrichtung an einer handwerkzeugmaschine |
JP2691914B2 (ja) | 1988-09-09 | 1997-12-17 | 株式会社リコー | 画像形成装置 |
US5018651A (en) * | 1988-12-27 | 1991-05-28 | Hull Harold L | Side or end dump article carrier |
US4922077A (en) | 1989-01-31 | 1990-05-01 | Raytheon Company | Method of laser marking metal packages |
DE3917153A1 (de) * | 1989-05-26 | 1990-11-29 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US4922007A (en) * | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
JP2985205B2 (ja) | 1990-01-25 | 1999-11-29 | ミノルタ株式会社 | 画像形成装置 |
JPH03226767A (ja) | 1990-01-31 | 1991-10-07 | Minolta Camera Co Ltd | 画像形成装置管理システム |
US5335048A (en) * | 1990-01-30 | 1994-08-02 | Minolta Camera Kabushiki Kaisha | Efficient control system of image forming apparatus |
US5356887A (en) * | 1990-01-31 | 1994-10-18 | Merck & Co., Inc. | Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids |
US5019651A (en) | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
JPH04151765A (ja) | 1990-10-16 | 1992-05-25 | Fujitsu Ltd | ファクシミリ装置の消耗品自動発注方式 |
SK279589B6 (sk) | 1991-11-22 | 1999-01-11 | Procter And Gamble Pharmaceuticals | Farmaceutický prípravok s retardovaným uvoľňovaním |
CA2124792C (en) | 1991-12-17 | 2000-07-04 | Ann D. Geddes | Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone |
JPH05224479A (ja) | 1992-02-10 | 1993-09-03 | Toshiba Corp | 画像形成装置 |
TW237386B (ru) | 1992-04-15 | 1995-01-01 | Ciba Geigy | |
DK0648120T3 (da) | 1992-06-30 | 1998-01-19 | Procter & Gamble Pharma | Anvendelse af phosphonater til behandling af osteoporose |
JPH06111039A (ja) | 1992-09-25 | 1994-04-22 | Toray Ind Inc | 光学読み取り識別マークの記録方法 |
US5358941A (en) * | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
JPH06250802A (ja) | 1993-02-22 | 1994-09-09 | Ricoh Co Ltd | プリンタ |
FR2703590B1 (fr) | 1993-04-05 | 1995-06-30 | Sanofi Elf | Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse . |
US5510517A (en) * | 1993-08-25 | 1996-04-23 | Merck & Co., Inc. | Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids |
US5431920A (en) * | 1993-09-21 | 1995-07-11 | Merck Frosst, Canada, Inc. | Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents |
JPH07239825A (ja) | 1994-02-28 | 1995-09-12 | Canon Inc | 状態通報方法およびそれを用いたネットワークシステム |
US20010007863A1 (en) | 1998-06-18 | 2001-07-12 | Merck & Co., Inc. | Wet granulation formulation for bisphosphonic acids |
TW390813B (en) | 1994-04-29 | 2000-05-21 | Merck & Co Inc | Wet granulation formulation for bisphosphonic acids |
GB9408775D0 (en) * | 1994-05-04 | 1994-06-22 | Ciba Geigy Ag | Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration |
US5462932A (en) * | 1994-05-17 | 1995-10-31 | Merck & Co., Inc. | Oral liquid alendronate formulations |
JPH07325514A (ja) | 1994-05-30 | 1995-12-12 | Ricoh Co Ltd | サプライ発注システム |
JPH08152825A (ja) | 1994-11-30 | 1996-06-11 | Mita Ind Co Ltd | 画像形成装置の管理システム |
JPH08152814A (ja) | 1994-11-30 | 1996-06-11 | Mita Ind Co Ltd | 画像形成装置の管理システム |
FR2727629A1 (fr) | 1994-12-06 | 1996-06-07 | Sanofi Sa | Trousse pour cycle de traitement de l'osteoporose |
JP3261900B2 (ja) | 1994-12-13 | 2002-03-04 | 村田機械株式会社 | ファクシミリ装置 |
AU701258B2 (en) | 1994-12-28 | 1999-01-21 | Gador S.A. | Bone mass anabolic composition comprising olpadronate |
JPH08211792A (ja) | 1995-02-03 | 1996-08-20 | Mita Ind Co Ltd | 画像形成装置の管理システム |
KR19980702210A (ko) * | 1995-02-17 | 1998-07-15 | 폴락 돈나 엘 | 비척추골 골절의 위험률을 감소시키는 방법 |
US20010051616A1 (en) * | 1995-02-17 | 2001-12-13 | David B. Karpf | Method of lessening the risk of vertebral fractures |
JPH08315052A (ja) | 1995-05-18 | 1996-11-29 | Ricoh Co Ltd | 自動発注システム |
JPH08310007A (ja) * | 1995-05-19 | 1996-11-26 | Oki Data:Kk | シリアルプリンタ |
JPH09120238A (ja) | 1995-10-25 | 1997-05-06 | Canon Inc | 出力装置 |
JPH09156123A (ja) | 1995-12-04 | 1997-06-17 | Brother Ind Ltd | プリンタ |
JPH09185474A (ja) | 1995-12-27 | 1997-07-15 | Fuji Xerox Co Ltd | 印刷管理装置 |
JP3363680B2 (ja) | 1995-12-28 | 2003-01-08 | ブラザー工業株式会社 | カートリッジの真偽判別方法及びそれを利用した出力装置 |
JPH09259355A (ja) | 1996-03-21 | 1997-10-03 | Oki Electric Ind Co Ltd | 梱包された商品の確認処理システム |
DE19615812A1 (de) | 1996-04-20 | 1997-10-23 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation |
US5930553A (en) * | 1997-04-25 | 1999-07-27 | Hewlett-Packard Company | Image forming and office automation device consumable with memory |
US5730715A (en) * | 1996-06-14 | 1998-03-24 | Becton Dickinson And Company | Method for the iontophoretic administration of bisphosphonates |
US5781405A (en) * | 1996-09-30 | 1998-07-14 | Gateway 2000, Inc. | Electronic device having rotatably mounted infrared device with a pair of pegs fitting into a pair of holes |
US6572874B1 (en) * | 1998-05-15 | 2003-06-03 | Umd, Inc. | Vaginal delivery of bisphosphonates |
US6905701B2 (en) | 1997-06-11 | 2005-06-14 | Umd, Inc. | Formulations for transmucosal vaginal delivery of bisphosphonates |
US6015801A (en) * | 1997-07-22 | 2000-01-18 | Merck & Co., Inc. | Method for inhibiting bone resorption |
US6432932B1 (en) * | 1997-07-22 | 2002-08-13 | Merck & Co., Inc. | Method for inhibiting bone resorption |
ID24096A (id) * | 1997-07-22 | 2000-07-06 | Merck & Co Inc | Metode untuk menghambat resorpsi tulang |
US5994329A (en) * | 1997-07-22 | 1999-11-30 | Merck & Co., Inc. | Method for inhibiting bone resorption |
SE9703691D0 (sv) | 1997-10-10 | 1997-10-10 | Astra Ab | Pharmaceutical compositions |
US6124314A (en) * | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
JP3065053B2 (ja) * | 1998-01-06 | 2000-07-12 | セイコーエプソン株式会社 | 機器監視システム、ローカル監視装置、統合監視装置、機器監視方法、及び、プログラムを格納したコンピュータ可読媒体 |
EP1088333A4 (en) | 1998-06-24 | 2005-08-10 | Merck & Co Inc | METHOD AND COMPOSITIONS FOR CONNECTING OSTEOPROSIS |
US6816968B1 (en) * | 1998-07-10 | 2004-11-09 | Silverbrook Research Pty Ltd | Consumable authentication protocol and system |
IT1303672B1 (it) | 1998-07-28 | 2001-02-23 | Nicox Sa | Sali nitrati di farmaci attivi nei disordini ossei |
US6494562B1 (en) * | 1998-09-03 | 2002-12-17 | Hewlett-Packard Company | Method and apparatus for identifying a sales channel |
FR2784031B1 (fr) | 1998-10-02 | 2002-02-01 | Sanofi Elf | Utilisation de derives de l'acide bisphosphonique pour la preparation d'un medicament destine au traitement des boiteries |
EP0998933A1 (de) | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation |
EP0998932A1 (de) * | 1998-10-09 | 2000-05-10 | Boehringer Mannheim Gmbh | Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung |
US6331533B1 (en) * | 1998-11-16 | 2001-12-18 | Merck & Co., Inc. | Method for inhibiting dental resorptive lesions |
JP3793023B2 (ja) * | 1998-12-04 | 2006-07-05 | ロシュ ダイアグノスティックス ゲーエムベーハー | 体内プロテーゼの骨統合を促進するためのイバンドロネートの使用 |
TW442666B (en) | 1998-12-22 | 2001-06-23 | Minolta Co Ltd | Zoom lens system |
KR100415490B1 (ko) * | 1999-01-11 | 2004-01-24 | 프라운호퍼-게젤샤프트 츄어 푀르더룽 데어 안게반텐 포르슝에.파우. | 파워 모스 소자 및 그 제조 방법 |
JP2002541223A (ja) | 1999-04-09 | 2002-12-03 | カロ バイオ アクチェブラーグ | エストロゲンレセプター及び骨 |
SE9901272D0 (sv) | 1999-04-09 | 1999-04-09 | Astra Ab | New improved formulation |
CA2308532C (en) | 1999-05-12 | 2005-11-29 | Gador S.A. | Use of bisphosphonates for the treatment of osteogenesis imperfecta |
PL351674A1 (en) | 1999-05-21 | 2003-05-19 | Novartis Ag | Use of bisphosphonic acids for treating angiogenesis |
US6965411B1 (en) * | 1999-06-24 | 2005-11-15 | Jones Richard A | Remote camera positioner |
AR024462A1 (es) | 1999-07-01 | 2002-10-02 | Merck & Co Inc | Tabletas farmaceuticas |
US6903836B2 (en) * | 1999-09-10 | 2005-06-07 | Hewlett-Packard Development Company, L.P. | Hard copy cost recovery systems, an apparatus for tracking usage information for a hard copy device, hard copy devices, and a usage accounting method |
US6793934B1 (en) * | 1999-12-08 | 2004-09-21 | Shire Laboratories, Inc. | Solid oral dosage form |
US6285060B1 (en) * | 1999-12-30 | 2001-09-04 | Siliconix Incorporated | Barrier accumulation-mode MOSFET |
JP2001253827A (ja) * | 2000-02-15 | 2001-09-18 | Pfizer Prod Inc | 骨粗鬆症を治療するための組成物および方法 |
US20020004218A1 (en) * | 2000-03-31 | 2002-01-10 | Rodan Gideon A. | Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase |
WO2001076592A1 (en) | 2000-04-06 | 2001-10-18 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neural regeneration |
US6468559B1 (en) * | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
GB0012209D0 (en) | 2000-05-19 | 2000-07-12 | Novartis Ag | Organic compounds |
EP1296689B3 (en) | 2000-06-20 | 2013-02-13 | Novartis AG | Method of administering bisphosphonates |
US6476006B2 (en) | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
HUP0303700A3 (en) * | 2000-07-17 | 2006-07-28 | Astellas Pharma Inc Chuo Ku | Pharmaceutical composition improved in peroral absorbability |
US6638920B2 (en) * | 2000-07-21 | 2003-10-28 | Merck & Co., Inc. | Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses |
US6750213B2 (en) * | 2000-10-19 | 2004-06-15 | Merck & Co., Inc. | Estrogen receptor modulators |
MXPA03006565A (es) | 2001-01-23 | 2005-07-29 | Gador Sa | Composicion comprendiendo bisfosfonatos para la prevencion y/o tratamiento de enfermedades metabolicas de huesos, proceso para preparar tal composicion y el uso de la misma. |
AR034199A1 (es) | 2001-02-01 | 2004-02-04 | Riderway Corp | Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion |
JP2004527479A (ja) | 2001-02-06 | 2004-09-09 | ザ ロイヤル アレクサンドラ ホスピタル フォー チルドレン | 骨壊死の治療用および骨壊死の発症のリスクのある患者のマネージメント用医薬 |
KR20030083725A (ko) | 2001-03-01 | 2003-10-30 | 에미스페어 테크놀로지스, 인코포레이티드 | 비스포스포네이트 전달용 조성물 |
JP2004530684A (ja) | 2001-05-10 | 2004-10-07 | メルク エンド カムパニー インコーポレーテッド | エストロゲン受容体モジュレーター |
US6998678B2 (en) * | 2001-05-17 | 2006-02-14 | Infineon Technologies Ag | Semiconductor arrangement with a MOS-transistor and a parallel Schottky-diode |
JP2005516928A (ja) | 2001-12-13 | 2005-06-09 | メルク エンド カムパニー インコーポレーテッド | 骨異常のためのビスホスホネート液体製剤 |
US20050070504A1 (en) * | 2001-12-21 | 2005-03-31 | The Procter & Gamble Co. | Risedronate compositions and their methods of use |
TWI349553B (en) * | 2001-12-21 | 2011-10-01 | Procter & Gamble | Kit and use of bisphosphonate for treating high bone turnover |
DE10207309B4 (de) * | 2002-02-21 | 2015-07-23 | Infineon Technologies Ag | MOS-Transistoreinrichtung |
US7488496B2 (en) * | 2002-03-06 | 2009-02-10 | Christer Rosen | Effervescent compositions comprising bisphosphonates and methods related thereto |
PL372920A1 (en) | 2002-03-13 | 2005-08-08 | Merck & Co,Inc. | Fluorinated 4-azasteroid derivatives as androgen receptor modulators |
US20050176685A1 (en) | 2002-04-05 | 2005-08-11 | Daifotis Anastasia G. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
MXPA04009586A (es) | 2002-05-10 | 2005-01-11 | Hoffmann La Roche | Acidos bisfosfonicos para el tratamiento y prevencion de la osteoporosis. |
SI1596870T2 (sl) | 2002-12-20 | 2011-07-29 | Hoffmann La Roche | Formulacija z visokim odmerkom ibandronata |
GB0424543D0 (en) * | 2004-11-05 | 2004-12-08 | Varintelligent Bvi Ltd | Driving method for high frame rate display system |
-
2003
- 2003-05-02 MX MXPA04009586A patent/MXPA04009586A/es active IP Right Grant
- 2003-05-02 NZ NZ556278A patent/NZ556278A/en not_active IP Right Cessation
- 2003-05-02 SI SI200331018T patent/SI1506041T1/sl unknown
- 2003-05-02 AU AU2003229770A patent/AU2003229770B2/en not_active Ceased
- 2003-05-02 PT PT70143623T patent/PT1880744E/pt unknown
- 2003-05-02 PL PL03371346A patent/PL371346A1/xx not_active Application Discontinuation
- 2003-05-02 CN CNA2006101363686A patent/CN1939314A/zh active Pending
- 2003-05-02 ES ES07014362.3T patent/ES2532393T3/es not_active Expired - Lifetime
- 2003-05-02 RU RU2004129324/15A patent/RU2329809C2/ru not_active IP Right Cessation
- 2003-05-02 EP EP20070014362 patent/EP1880744B1/en not_active Revoked
- 2003-05-02 BR BR0308901-0A patent/BR0308901A/pt not_active Application Discontinuation
- 2003-05-02 KR KR1020127011286A patent/KR20120065435A/ko not_active Application Discontinuation
- 2003-05-02 RU RU2008103617/14A patent/RU2387451C2/ru not_active IP Right Cessation
- 2003-05-02 KR KR1020157010154A patent/KR20150053811A/ko not_active Application Discontinuation
- 2003-05-02 JP JP2004503108A patent/JP2005522526A/ja active Pending
- 2003-05-02 NZ NZ535705A patent/NZ535705A/en not_active IP Right Cessation
- 2003-05-02 CA CA2481142A patent/CA2481142C/en not_active Expired - Fee Related
- 2003-05-02 DE DE60317061T patent/DE60317061T2/de not_active Expired - Lifetime
- 2003-05-02 CN CNB038075652A patent/CN100551377C/zh not_active Expired - Fee Related
- 2003-05-02 KR KR1020047015694A patent/KR100642961B1/ko active IP Right Review Request
- 2003-05-02 CA CA2763775A patent/CA2763775C/en not_active Expired - Fee Related
- 2003-05-02 WO PCT/EP2003/004629 patent/WO2003095029A1/en active Application Filing
- 2003-05-02 PL PL399493A patent/PL399493A1/pl unknown
- 2003-05-02 ES ES03722591T patent/ES2294277T3/es not_active Expired - Lifetime
- 2003-05-02 EP EP10179327A patent/EP2308563A1/en not_active Ceased
- 2003-05-02 SI SI200332418T patent/SI1880744T1/sl unknown
- 2003-05-02 PT PT03722591T patent/PT1506041E/pt unknown
- 2003-05-02 EP EP14184790.5A patent/EP2851105A1/en not_active Withdrawn
- 2003-05-02 DK DK03722591T patent/DK1506041T3/da active
- 2003-05-02 KR KR1020137034838A patent/KR20140021045A/ko active Application Filing
- 2003-05-02 KR KR1020097004578A patent/KR20090029312A/ko active Application Filing
- 2003-05-02 EP EP03722591A patent/EP1506041B1/en not_active Revoked
- 2003-05-02 AT AT03722591T patent/ATE376444T1/de active
- 2003-05-02 KR KR1020067008979A patent/KR20060058151A/ko not_active Application Discontinuation
- 2003-05-02 DK DK07014362.3T patent/DK1880744T3/en active
- 2003-05-02 KR KR1020097019891A patent/KR20090106663A/ko active Search and Examination
- 2003-05-06 TW TW092112340A patent/TWI347188B/zh not_active IP Right Cessation
- 2003-05-06 US US10/430,007 patent/US7410957B2/en not_active Expired - Fee Related
- 2003-05-06 PA PA20038573101A patent/PA8573101A1/es unknown
- 2003-05-07 PE PE2003000447A patent/PE20040440A1/es not_active Application Discontinuation
- 2003-05-08 AR ARP030101609A patent/AR039978A1/es not_active Application Discontinuation
- 2003-05-08 MY MYPI20071758A patent/MY146809A/en unknown
- 2003-05-08 MY MYPI20031738A patent/MY140080A/en unknown
- 2003-05-09 UY UY27802A patent/UY27802A1/es not_active Application Discontinuation
- 2003-05-09 GT GT200300107A patent/GT200300107A/es unknown
-
2004
- 2004-06-09 IL IL17437104A patent/IL164371A0/xx unknown
- 2004-10-01 EC EC2004005335A patent/ECSP045335A/es unknown
- 2004-10-01 NO NO20044195A patent/NO328734B1/no not_active IP Right Cessation
- 2004-10-01 HR HR20040906 patent/HRP20040906B1/xx not_active IP Right Cessation
- 2004-10-01 ZA ZA2004/07950A patent/ZA200407950B/en unknown
- 2004-10-03 IL IL164371A patent/IL164371A/en active IP Right Grant
- 2004-11-29 US US10/998,849 patent/US7192938B2/en not_active Expired - Fee Related
-
2006
- 2006-01-05 HK HK06100194.8A patent/HK1080409A1/xx not_active IP Right Cessation
- 2006-03-27 US US11/390,227 patent/US20060166938A1/en not_active Abandoned
-
2007
- 2007-07-06 AR ARP070103036A patent/AR061845A2/es not_active Application Discontinuation
-
2008
- 2008-01-11 CY CY20081100046T patent/CY1108105T1/el unknown
- 2008-06-16 US US12/139,587 patent/US7718634B2/en not_active Expired - Fee Related
- 2008-11-17 JP JP2008293614A patent/JP5813911B2/ja not_active Expired - Fee Related
-
2010
- 2010-02-08 AU AU2010200438A patent/AU2010200438B2/en not_active Ceased
- 2010-03-31 NO NO20100477A patent/NO331024B1/no not_active IP Right Cessation
- 2010-04-08 US US12/756,376 patent/US20100197637A1/en not_active Abandoned
- 2010-04-22 IL IL205262A patent/IL205262A/en unknown
-
2013
- 2013-04-19 JP JP2013088493A patent/JP6067466B2/ja not_active Expired - Lifetime
- 2013-12-02 JP JP2013249105A patent/JP5837552B2/ja not_active Expired - Lifetime
-
2014
- 2014-12-22 JP JP2014258163A patent/JP2015083592A/ja active Pending
-
2015
- 2015-03-30 CY CY20151100307T patent/CY1116233T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2004129324A (ru) | Применения бисфосфоновых кислот для лечения и профилактики остеопороза | |
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
US7939522B1 (en) | Dosage formulations for acetylcholinesterase inhibitors | |
CA2601289A1 (en) | Once-a-day oxycodone formulations | |
HUP0400607A2 (hu) | Orális szabályozott hatóanyag-leadású készítmény szív- és keringési betegségek napi egyszeri gyógyszerezéssel való kezelésére és megelőzésére | |
RU2003119545A (ru) | Фармацевтические композиции для перорального введения фамакологических действующих веществ | |
DK0833643T3 (da) | Formuleringer af vandfrit mononatriumsalt af alendronat og deres anvendelse til behandling af knoglesygdomme | |
FI3982960T3 (fi) | Perinnöllisen angioödeeman hoitoja | |
RU2003100507A (ru) | Фармацевтические композиции | |
CN101146542A (zh) | 利塞膦酸盐组合物及其使用方法 | |
HUP0401429A2 (hu) | Lumirakoxibot tartalmazó gyógyszerkészítmény | |
CA2529604A1 (en) | Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form | |
WO2001089494A3 (en) | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | |
HK1087039A1 (en) | Use of biphosphonate in preparing medical kit and a kit used for increasing bone mass | |
JP4786127B2 (ja) | 色素沈着改善治療薬 | |
EP1880722B1 (en) | Pharmaceutical compositions of ciprofloxacin | |
RU2004131214A (ru) | Способы лечения когнитивных расстройств | |
RU2005135647A (ru) | Комбинации, включающие пароксетин и {1-(r)-(3.5-бис-трифтор-2-метилфенил) этилметиламид}-2-(s)-(4-фтор-2-метилфенил) пиперазин-1-карбоновой кислоты, для лечения депрессии и/или тревоги | |
RU2002129298A (ru) | Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера | |
US20040058909A1 (en) | Method of treatment | |
ES2668943T3 (es) | Composición farmacéutica para tratar eyaculación precoz y método de tratamiento de la eyaculación precoz | |
RU2003100081A (ru) | Способы и композиции, в которых используется сулодексид, для лечения диабетической нефропатии | |
CA2480275A1 (en) | Statin therapy for enhancing cognitive maintenance | |
WO2019145926A1 (en) | Stable thiamine containing pharmaceutical formulations | |
CA2368352A1 (en) | Method for treating neurodegeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC41 | Official registration of the transfer of exclusive right |
Effective date: 20180613 |
|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20200503 |